OncoMatch/Clinical Trials/NCT06621199
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
Is NCT06621199 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Mitoxantrone hydrochloride liposome and Cytarabine for acute myeloid leukemia.
Treatment: Mitoxantrone hydrochloride liposome · Cytarabine · Venetoclax — This is a phase 2 study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome in combination with cytarabine and venetoclax (MAV) regimen in newly diagnosed elderly AML. To account, conservatively, for a 10% dropout rate before study completion, we planned to include 42 patients. The primary endpoint is 2-year event free survival(EFS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anthracycline
Subjects who have received anthracycline pretreatment
Cannot have received: anti-AML treatments
Exception: except for hydroxyurea, leukapheresis and other leukocyte-lowering treatments
Subjects who have received...other anti-AML treatments (except for hydroxyurea, leukapheresis and other leukocyte-lowering treatments)
Lab requirements
Kidney function
Serum creatinine≤1.5 ULN
Liver function
ALT/AST≤2.5 ULN (for subjects with hepatic infiltration≤5 ULN); Total bilirubin≤1.5 ULN (for subjects with hepatic infiltration≤3 ULN)
Cardiac function
Long QTc syndrome or QTc interval >480 ms; Complete left bundle branch block, degree II or III atrioventricular block; Severe, uncontrolled arrhythmia requiring medical treatment; NYHA classification ≥ grade II; Cardiac ejection fraction (EF) <50%; History of myocardial infarction, unstable angina, severely unstable ventricular arrhythmia or any other arrhythmia requiring treatment, clinically severe pericardial disease, or ECG evidence of acute ischemic or active conduction abnormalities within 6 months prior to enrollment
ALT/AST≤2.5 ULN (for subjects with hepatic infiltration≤5 ULN); Total bilirubin≤1.5 ULN (for subjects with hepatic infiltration≤3 ULN); Serum creatinine≤1.5 ULN. Cardiac function and disease conform to one of the following conditions: Long QTc syndrome or QTc interval >480 ms; Complete left bundle branch block, degree II or III atrioventricular block; Severe, uncontrolled arrhythmia requiring medical treatment; NYHA classification ≥ grade II; Cardiac ejection fraction (EF) <50%; History of myocardial infarction, unstable angina, severely unstable ventricular arrhythmia or any other arrhythmia requiring treatment, clinically severe pericardial disease, or ECG evidence of acute ischemic or active conduction abnormalities within 6 months prior to enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify